The Sidney Kimmel Comprehensive Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Employees
- -
- Market Cap
- -
Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- Drug: Luteinizing hormone-releasing hormone (LHRH) analogue
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-02-25
- Target Recruit Count
- 50
- Registration Number
- NCT06059118
- Locations
- 🇺🇸
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
- Conditions
- Fibrolamellar Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 27
- Registration Number
- NCT06027086
- Locations
- 🇺🇸
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 219
- Registration Number
- NCT06014255
- Locations
- 🇺🇸
Northewestern University, Chicago, Illinois, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸XCancer - Omaha, LLC, Omaha, Nebraska, United States
Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
- Conditions
- Billiary Track Cancer
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2025-04-03
- Target Recruit Count
- 27
- Registration Number
- NCT06001658
- Locations
- 🇺🇸
SKCCC Johns Hopkins, Baltimore, Maryland, United States
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
- Conditions
- Lung CancerGastrointestinal CancerHead and Neck Cancer
- Interventions
- Other: Collection of biological specimens
- First Posted Date
- 2023-08-16
- Last Posted Date
- 2024-08-28
- Target Recruit Count
- 1250
- Registration Number
- NCT05995821
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2025-02-19
- Target Recruit Count
- 15
- Registration Number
- NCT05977907
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Providence Cancer Institute, Portland, Oregon, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC
- Conditions
- NSCLC Stage IVALK Fusion Protein Expression
- Interventions
- Biological: Peptide vaccine
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2024-05-21
- Target Recruit Count
- 12
- Registration Number
- NCT05950139
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Pre-operative Hypofractionated Proton Therapy
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Radiation: hypofractionation
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2025-04-13
- Target Recruit Count
- 40
- Registration Number
- NCT05917301
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
- Conditions
- T-cell Prolymphocytic LeukemiaMyelomonocytic Leukemia, ChronicCMLPlasma Cell LeukemiaLeukemia, AcuteMyelodysplastic SyndromesMultiple MyelomaMyeloproliferative Disorders
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-03-08
- Target Recruit Count
- 32
- Registration Number
- NCT05823571
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: Dose Escalation -tagraxofusp-erzsDrug: Dose Expansion at RP2D -tagraxofusp-erzs
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 36
- Registration Number
- NCT05716009
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States